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Muscular fatigue and dyspnoea on exertion are among the most common symptoms in chronic heart failure; however their
origin is still poorly understood. Several studies have shown that cardiac dysfunction alone cannot fully explain their origin,
but the contribution of the multiorgan failure present in this syndrome must be highlighted. In this study, divided in two
parts (see part II: pp. 643–648), we aimed to summarize the existing evidence and the most controversial aspects of the
complex interplay of different factors involved in symptom generation. In this first part of the review, six key factors are
revised: the heart, the lung, the skeletal muscle, the hormonal changes, the O2 delivery to the periphery, the endothelium. In
the second part, the role of the excitatory reflexes and the cardiac cachexia will be presented, and finally, the potential
therapeutic implications are discussed. We believe that a better knowledge of the pathophysiology of this syndrome may
contribute to the management of the patients and to the improvement in their stress tolerance and quality of life. Eur J
Cardiovasc Prev Rehabil 17:637–642 c 2010 The European Society of Cardiology
European Journal of Cardiovascular Prevention and Rehabilitation 2010, 17:637–642
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The problem: origin of symptoms in
heart failure
Chronic heart failure (CHF) is a multisystem syndrome.
Although initiated by a reduction in cardiac function, it is
characterized by the activation of compensatory mechanisms,
which involve the whole body: haemodynamic, autonomic
and neuro-humoral changes may be initially beneficial,
but subsequently become detrimental and lead to
perpetuation of the syndrome [1]. These, once activated,
are responsible for severe changes in many vital organs
and may generate symptoms. Muscular fatigue and
dyspnoea are the more common symptoms in CHF;
however their origin is still poorly understood [2]. Several
studies have shown that changes in cardiac function
cannot fully explain their origin [3]. Interventional studies
have also opposed a concept of central haemodynamics as
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the sole determinant of exercise capacity in CHF: pharma-
cological agents, which increase cardiac output (dobuta-
mine) and/or reduce pulmonary capillary wedge pressure
(hydralazine) do not result in an immediate increase in
exercise capacity. Better knowledge of the pathophysiology
of this syndrome may contribute to the management of the
patients and to the improvement in their stress tolerance
and quality of life [4].
This position study, divided into two parts, endorsed by
the ‘Exercise Physiology, Sport Cardiology and Cardiac
Rehabilitation’ Working Group of the Italian Society of
Cardiology (Italian Federation of Cardiology), summarizes
the existing evidence of the complex interplay of dif-
ferent factors involved in symptom generation in CHF
because of systolic dysfunction. The roles of the key
factors are revised and therapeutic implications are dis-
cussed here. In this first part of the review, the con-
tributions of the heart, the lung, the skeletal muscle, the
hormonal changes, the O2 delivery to the periphery and
the endothelium are presented. In the second part, the
roles of the excitatory reflexes and the cardiac cachexia
will be presented, and finally, the potential therapeutic
implications are discussed.
Table 1 summarizes the various causes of the two major
CHF symptoms, dyspnoea and fatigue, and the relative
contribution of the above considered factors.
The heart
Intuitively, central haemodynamics, and the heart in
particular, should be the major determinants of exercise
capacity. There are several items in favour of this con-
cept. Exercise capacity (expressed as peak O2 consump-
tion or peakVO2) is strictly related to cardiac output on
the basis of the Fick principle
peakVo2 ¼ CardiacOutput ðA  VÞO2 diff
¼ Stroke VolumeHeart Rate
ðA  VÞO2 diff
where (A – V), O2 difference is arterio–venous O2
difference, which is usually similar between normal
individuals and CHF patients [5]. Thus, exercise
intolerance is mainly related to heart function and its
chronotropic response, both altered in CHF. In keeping
with this, in CHF secondary to idiopathic cardiomyopathy,
the cardiac response to low-dose dobutamine, assessed
by echocardiography, is correlated with peakVO2 [6]. This
not only suggests the importance of the pump function,
but also that low-dose dobutamine, which is insensitive
to factors such as skeletal muscle deconditioning or
poor motivation, is a valuable alternative technique to
peakVO2 determination for assessing the severity of the
disease. Furthermore, many heart abnormalities, such as
arrhythmias (abnormal heart rate or rhythm) or valve
diseases, if severe enough, can cause shortness of breath
and/or exercise intolerance.
The leading role of pump function has been challenged
by several evidences of poor relationship between resting
left ventricular (LV) systolic function and peakVO2 [7].
Recently, the role of the heart has been emphasized, but
that different indices of LV dysfunction (and not just
ejection fraction) need to be monitored, for example,
indices of longitudinal LV function assessed by tissue
Doppler imaging [8]. Furthermore, LV asynchrony, rather
than uniform depression of systolic ventricular function,
may play a key role in determining the maximum exercise
tolerance by prolonging the total isovolumic period within
the cardiac cycle [9]. The important contribution of
electromechanical conduction delays to symptom gen-
eration has been further confirmed [10], regardless of
baseline LV systolic dysfunction severity [10]. These
findings might also explain the inconsistent effect of
positive inotropic agents [11], whose efficacy may be
conditioned by the substratum of the myocardial disease.
Importantly, the strong relationship between diastolic
abnormalities and exercise limitation should be not under-
scored [12,13]. Severity of effort intolerance is linked
with LV filling pressure, and consequently, therapeutic
interventions that lower this pressure may enhance
exercise capacity.
The lung
A modified lung physiology is an important determinant of
exercise intolerance, ventilation inefficiency and dyspnoea
sensation in CHF [14]. Classically, the initial source of
injury to the lung is an impaired LV haemodynamic because
of increased LV filling pressure and consequent untoward
backward injury on the pulmonary capillary bed. The
consequences of these haemodynamic perturbations are
two-fold: (i) changes in lung airways function and
mechanical properties, (ii) development of gas exchange
abnormalities because of alveolar–capillary injury and
dysfunction. Both play a key role in the limitation of
maximal exercise performance and may significantly affect
the physiological linear ventilatory response to maximal
exercise. It is also possible that a damaged endothelium
(see chapter 6) may play a critical role in lung dysfunction.
An excessive ventilatory requirement during incremental
workloads is typical of CHF and is conventionally
identified as an increased relationship between the rise
in ventilation and the rate of carbon dioxide elimination
Table 1 Contribution of different mechanisms to exercise
intolerance symptom in heart failure
Factor Dyspnoea Muscle fatigue
Heart + ±
Lung + + ±
Muscle ± + + +
Hormonal changes + +
Oxygen delivery ± + +
Endothelium + + +
Excitatory reflexes + + +
Cardiac cachexia ± + + +
638 European Journal of Cardiovascular Prevention and Rehabilitation 2010, Vol 17 No 6
Copyright © The European Society of Cardiology. Unauthorized reproduction of this article is prohibited. at Centro Cardiologico Monzino on July 26, 2012cpr.sagepub.comDownloaded from 
(VE/VCO2). The VE/VCO2, either measured in specific
exercise periods [15] or during the entire exercise (or
the greatest part of exercise) as VE/VCO2 slope, has a
remarkable value for risk stratification and prognostic
prediction [16]. The increased VE/VCO2 slope is
ascribable to high dead space ventilation, low CO2 partial
pressure and/or abnormal ventilatory control mechanisms,
with convincing evidence presented for all these putative
mechanisms. The next subheadings briefly focus on the
pulmonary determinants of an augmented VE/VCO2.
Airways function abnormalities
Mechanical lung properties of CHF patients are primarily
challenged by an increased stiffness whose entity
depends on the severity and duration of the disease.
Major pathogenetic bases for lung stiffening are inter-
stitial lung congestion and heart to lung pathological
interaction because of cardiomegaly, vascular engorge-
ment, increased alveolar surface tension, unequal ventila-
tion and activation of contractile elements of the vascular
wall [17]. The combination of these factors leads to the
development of a typical restrictive lung pattern [18,19].
According to Wasserman, the lung restriction may occur as
a function of haemodynamic derangement, suggesting a
pathogenetic role of an increased wasted ventilation with
those patients with higher VE/VCO2 slope exhibiting the
higher dead space to tidal volume ratio and a premature
increase in respiratory rate as a compensatory mechanism.
In agreement with this, some degree of reversal in
pulmonary restriction and improvement in the ventilatory
response to exercise were shown after ultrafiltration, and
afterload reduction with dialysis with lung decongestion,
emphasizing the role of fluid overload [20].
Lung diffusion abnormalities
Diffusion changes and gas exchange inefficiency occur
mainly in the setting of diastolic CHF [21]. As for
abnormalities in lung mechanics, pressure elevation in
the pulmonary circulation is the initial source of injury to
the anatomical integrity and functional properties of lung
capillaries and alveolar spaces (i.e. the blood gas barrier);
this can be studied by evaluating gas diffusion for carbon
monoxide or nitric oxide techniques (DLCO and DLNO,
respectively). A low DLCO relates with disease severity
and increased pulmonary vascular resistances [22]. For a
given haemoglobin (Hb) concentration, these changes are
primarily driven by a reduction in alveolar membrane
component (Dm) rather than changes in capillary blood
volume [23]. A correlation between alveolar–arterial O2
gradient, DLCO and peak VO2, and between Dm and VE/
VCO2 slope were shown supporting the role of lung
diffusion abnormalities [24].
The skeletal muscle
A key role of the periphery has emerged, generating the
‘muscle hypothesis’, where exertional dyspnoea and
fatigue are resulting from skeletal muscle disorders, also
because of deconditioning [25]. These disorders are
responsible for the maintenance and progression of the
systemic abnormalities, at neurohormonal level, leading
to a vicious circle. This constitutes the physiological basis
for the benefit of physical conditioning in prognosis
(Fig. 1).
Intrinsic modifications in muscle composition (and not
only blood flow reduction) play a major role: qualitative
and quantitative changes, such as muscle wastage [26]
and shift from slow (fatigue resistant) to fast (fatigue
non-resistant) fibre type, reduction in mitochondrial
density and enzymes are likely to be involved [27]. An
imbalance between protein synthesis and degradation
with resultant cachectic status (see chapter 8, part II)
plays an important role in symptoms. Programmed cell
death has been found both in skeletal muscle and
interstitial cells [28].
The regulation of fibre type involves the growth hormone/
insulin-like growth factor-1/calcineurin/transcriptional co-
activator PGC1-a cascade [29], whereas mechanisms
leading to muscle wastage, protein degradation can occur
through cytokine-triggered skeletal muscle apoptosis,
but also through ubiquitin/proteasome and nonubiquitin-
dependent pathways [30]. The systems controlling
ubiquitin/proteasome activation are triggered by tumour
necrosis factor a and growth hormone/insulin-like growth
factor 1 [31]. Apoptosis correlates with the severity,
triggered by tumour necrosis factor a: it can be induced
by its second messenger sphingosine in-vitro experiments
with activation of caspases 3 and 9 and mitochondrial
cytochrome c release [32].
Furthermore, other factors contribute to muscle dysfunc-
tion. In the muscle, high levels of oxidation depressed
peak force generation and slowed contraction and
relaxation times [33]. A chronic inflammatory status is
associated with elevation of proinflammatory cytokines:
inducible NO synthase (NOS) production and oxidative
stress are sufficient to activate nuclear factor-kappa B, a
transcription factor for proinflammatory cytokine gene
expression that contributes to muscle damage. Oxidation
of sarcomeric proteins, such as myosin heavy chains,
tropomyosin and actin lead to contractile impairment and
muscle fatigue [34].
The hormonal changes
Neurohormonal response to heart damage may be con-
sidered a physiological compensatory response, aimed at
maintaining an adequate circulatory support particularly
during stress. Cardiac output is sustained through an in-
crease in plasma volume, heart rate and contractility.
These responses are elicited by activation of adrenergic
drive to heart and vessels, parasympathetic withdrawal,
increased renin–angiotensin–aldosterone system activation
Exercise intolerance in chronic heart failure Piepoli et al. 639
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[35] associated with a vasoconstrictive endothelial res-
ponse by endothelin secretion [36] and vasopressin
release [37]. However, chronically maintained neuroendo-
crine activation becomes detrimental and leads to the overt
clinical picture of CHF. Autonomic imbalance exerts a
proarrhythmic and profibrotic effects, sodium-water reten-
tion with increased extravascular water and peripheral and
lung oedema (leading to dypneoa). Arteriolar vasoconstric-
tion provokes negative effect in trophism and function of
skeletal muscles, renal hypoperfusion and dysfunction
(leading to fatigue).
At organ level, neurohormonal activation supports the
ventricular, vascular and tissue remodelling processes,
associated with alterations at structural level, by ongoing
cell apoptosis and necrosis, hypertrophy, fibrosis, leading
to irreversible morphofunctional changes in the heart,
peripheral muscles, lungs and kidney.
Plasma norepinephrine is an independent predictor of
mortality [38]. Thus counteraction of the activated
adrenergic nervous system and renin–angiotensin–aldos-
terone system constitutes the pathophysiological basis for
modern pharmacological treatment using neurohormonal
antagonists, namely b-blockers, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers and
aldosterone antagonists.
In a significant percentage, patients with CHF may
present with a ‘low triiodotironine status’, characterized
by reduced peripheral conversion of the thyroid prohor-
mone tetraiodotironine to the biologically active hormone
triiodotironine. Low triiodotironine level contributes to
the overall derangement of the neurohormonal control of
circulation and recognizes a prognostic role [39]. CHF is
associated with insulin resistance, characterized by both
fasting and stimulated hyperinsulinaemia, which may in-
duce altered metabolism of skeletal and heart muscle [40].
Neurohormonal activation is associated in advanced
stages with immunoinflammatory flare, as indicated by
higher levels of some cytokines, such as tumor necrosis a
or interleukin 6, though targeted treatment has failed, up
to now, to improve the patient outcome [41].
Thus, a chronic ‘fly or fight’ adaptation takes place. The
overall predominance of sodium retention, vasocontric-
tive systems on the main counter regulatory system
is represented by cardiac endocrine function, that is,
the ability of atrial and ventricular cardiomyocites
under haemodynamic stress to produce and secrete
two peptide hormones (atrial and brain natriuretic
peptides) with potent natriuretic/vasodilator and anti-
hypertrophic/apoptotic properties [42]. Their assay may
guide the evaluation of efficacy of therapeutical efforts,
including physical aerobic training [43].
The role of cortisol and sexual hormones is, at present,
under intense evaluation. Indeed, high cortisol adminis-
tration prevents endothelium damage during acute coro-
nary syndrome and women seem to be more protected
from nocturnal periodic breathing both in the presence of
CHF or during high-altitude exposure.
The oxygen delivery to the periphery
Classically, O2 delivery is measured as cardiac output
times the arterial O2 content (CaO2). However, this is O2
delivery to the capillary, which does not consider the
O2 flow from the capillary to the mitochondria, where O2
partial pressure in the blood (pO2) is around 0mmHg.
Fig. 1
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CaO2 depends on Hb concentration, pO2 and the position
of the oxyhaemoglobin (Hb-O2) dissociation curve. The
latter, however, has little effect on CaO2. Indeed in the
absence of hypoxia in CHF, and in normal individuals, in
the systemic artery, the Hb-O2 dissociation curve is flat
on its upper part so that whatever shifts right ward or
leftward (acidosis, temperature and molecules such
as 2,3-diphosphoglycerate) do not have any significant
effect CaO2 [44].
In CHF cardiac output is low; its increase during exercise
is blunted and patients are often anaemic: all these
factors reduce CaO2. In the systemic artery, CaO2
increases during exercise, mainly above the anaerobic
threshold, because of an increase in Hb. Exercise-induced
haemo concentration is likely because of an oncotic effect
of increased intracellular lactates and lactate metabolites,
with a role of spleen contraction variable in the different
animal species [45].
In the capillaries, with exercise, pO2 progressively
reduces from around 100mmHg measured near the
arteriolar end up to 18mmHg at the venular end of the
vessels both in normal individuals and CHF patients [46].
Indeed, in a progressively increasing workload exercise,
pO2 reduces up to the anaerobic threshold, whereas
Hb-O2 reduces throughout the test because of acidosis
above the anaerobic threshold (Bohr Effect). The CHF
patients, however, show a less defined temporal beha-
viour of pO2 changes during exercise with an increase,
at end exercise from pO2 nadir, observed in 20% of cases.
This phenomenon is likely because of a mismatch be-
tween blood perfusion and O2 extraction in the muscle
fibres. Oxygen flow from the capillary to the mitochondria
depends on distance between the two, and, most import-
antly, on the type of tissues which O2 flow through. It is
likely that muscle fibrosis, and other chronic hypoxia-
related muscle fibre changes observed in CHF negatively
influence O2 flow to the mitochondria [47].
The endothelium
Endothelial dysfunction actively affects the impaired O2
delivery to the periphery. Endothelial dysfunction is a
hallmark finding in both experimental and clinical CHF
[48], and a decreased skeletal muscle vasodilatation in
response to exercise seems to be an important determi-
nant of exercise intolerance [49]. In normal individuals,
during exercise a progressive peripheral arterial vasodila-
tation is involved in the O2 delivery process and a signi-
ficant role in the regulation of working muscle perfusion
is played by flow-mediated release of endothelial vaso-
dilating substances [50].
This flow-mediated vasodilatation is because of the
attractive force of fluid flow or shear stress. The
endothelium senses shear stress by means of a mechano-
transducer apparatus that is not fully defined, but that
involves cytoskeletal deformation and the release of
endothelial agonists such as prostacyclin, endothelium-
derived hyperpolarizing factor and NO [51]. Exercise is
a physiological stimulus that increases shear stress in
the endothelial surface and the flow-stimulated release
of endothelium-derived NO plays a critical role in the
response to exercise. When the NOS pathway is altered
by the experimental administration of exogenous NOS
antagonists, exercise-induced redistribution of blood flow
to skeletal muscle is attenuated and exercise capacity is
impaired [52].
In CHF patients, abnormalities in endothelial synthesis
of NO increased synthesis of endotelin-1 and changes in
prostaglandin metabolism significantly contribute in the
impaired muscle blood flow distribution during exercise.
NOS inhibition significantly reduced the forearm vasodi-
latation response to handgrip exercise in normal indivi-
duals, but did not change the response in patients with
CHF suggesting that flow-induced NO-mediated vasodi-
latation during exercise is blunted in these patients [53].
In most CHF patients endothelial-mediated flow-depen-
dent vasodilatation may be reduced as a consequence of
physical deconditioning and the mechanistic evidence may
be unmasked by studying the effects of exercise training on
the endothelial function and exercise performance.
Selected local forearm training by repetitive handgrip
exercise is capable of significantly improving the brachial
artery endothelial response [54]. Regular long-term
physical exercise improves both basal endothelial NO
formation and agonist-mediated endothelium-dependent
vasodilatation of the skeletal muscle microvasculature of
the lower limb [55].
The correction of the endothelium dysfunction was
associated with a significant increase in exercise capacity.
Interestingly, even in stable optimally treated patients
receiving resynchronization therapy, a session of exercise
training improved the brachial artery flow-mediated endo-
thelial response and peakVO2 [56]. Whether after physi-
cal training a lack of changes in endothelial function may
help to identify patients with a worse clinical outcome
remains an open and relevant question.
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